NCT04948749 Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
| NCT ID | NCT04948749 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | ICAD - Intracranial Atherosclerotic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 792 participants |
| Start Date | 2021-07-02 |
| Primary Completion | 2026-12 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.
Eligibility Criteria
Inclusion Criteria: 1. Age from 18 to 85 years 2. Patients with ischemic stroke within 30 days of enrolment attributed to 70% to 99% stenosis of a major intracranial artery (internal carotid artery \[C4-C7\], middle cerebral artery \[M1\], vertebral artery \[V4\], or basilar artery) on CTA (According to WASID method) 3. The diameter of the target vessel between 2.0mm - 4.5mm 4. The stenosis lesion length ≤ 14 mm 5. Baseline modified Rankin Scale (mRS) score ≤ 3 6. Patient understands the purpose and requirements of the study, and has provided informed consent Exclusion Criteria: 1. Ischemic stroke occurred within 7 days before enrolment 2. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion (NOTE: an exception is allowed if stenosis or occlusion involves a single vertebral artery proximal to a symptomatic basilar artery stenosis and the contralateral vertebral artery is supplying the basilar artery) 3. Bilater